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Applicants were randomized either into a
group with a limited Medicare community
care service benefit and case management
or into a control group receiving their reg-
ular medical care.   Analyses assess whether
or not community care management af fect-
ed health care use.  A tendency toward
reduced expenditures was observed for 
the treatment group, combining all 
demonstration sites, and when observing
each separately.  These dif ferences were or
approached statistical significance in two
sites for Medicare Part A and Parts  A and
B expenditures averaged over 3 years.
Expenditure reductions approached budget
neutrality with program costs in two sites.
INTRODUCTION
Dementia is a highly disabling and
destructive condition that has high social
and political visibility due to its prevalence
(11.3 percent among those age 65 years or
over, 47.6 percent among those 85 years or
over) (Evans et al., 1990) and its effects on
family and community support systems.
Much of the analysis of cost for this popu-
lation has been concerned with imputing
the economic value of care provided by
family members, documenting acute and
long-term care costs (such as payments for
community-based services and nursing
home care), and estimating the indirect
costs of caregiving such as from stress and
burden of family members and earnings
foregone from employment (e.g., Ernst
and Hay, 1997; Max, Webber, and  Fox,
1995; Rice et al., 1993; Scharlach and Boyd,
1989; Stommel, Collins, and Given, 1994;
Weinberger et al., 1993; Wimo, Ljunggren,
and Winblad, 1997).  Some recent work
has examined the effects of dementia on
annual Medicare expenditures (Gruenberg,
Kaganova, and Hornbrook, 1996; Pope et
al., 1996; Weiner et al., 1998).
This article considers whether participa-
tion in a case management program by per-
sons with dementia affected their total
Medicare expenditures.  The case manage-
ment program’s involvement with the fami-
lies was expected to have an indirect effect
on such use and expenditures, even though
the program was not designed or imple-
mented so as to expressly coordinate with
primary care physicians.  Case manager
involvement may have affected the quality
of primary care through improved patient
advocacy, monitoring of health status
among clients and caregivers, and provi-
sion of instrumental support to caregivers.
Demonstration Program
The Medicare Alzheimer’s Disease
Demonstration and Evaluation consisted of
two basic components.  One was the
assignment of demonstration treatment
subjects to a case manager (either a social
worker or nurse) who worked with family
caregivers to plan and coordinate 
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community services, and when needed,
helped train caregivers about disease pro-
gression and the evolving commensurate
functional assistance tasks that caregivers
would have to perform.  The second com-
ponent was access to a special Medicare
benefit that allowed for the reimbursement
of community care services.
Two case management models were
implemented that differed by case manag-
er-to-client ratios and per-month service
expenditure ceilings for each client.  Model
A sites operated with a target case manag-
er-to-client ratio of 1:100 and had a monthly
community service reimbursement limit or
cap of $290 to $489 per month per client.
Model B sites operated with a target case
manager-to-client ratio of 1:30 and had a
slightly higher reimbursement limit of $430
to $699 per month per client.  The per
month reimbursement caps in each model
varied by site and over time due to regional
cost variations and inflation adjustments.
Regular Medicare services—hospital,
skilled nursing, home health, durable med-
ical equipment (DME), physician services,
and all other services normally reimbursed
under Medicare Parts A and B—continued
to be available.  Services reimbursed under
the demonstration’s special benefits includ-
ed: adult day care; homemaker/personal
care; housekeeping; general chore (i.e.,
heavy cleaning); companion (e.g., friendly
visiting, caretaking while caregiver attend-
ed educational and/or support groups);
non-emergency transportation for client;
adaptive and assistive equipment (not oth-
erwise reimbursed as DME under Part B);
medical supplies used in conjunction with
skilled and unskilled home care (not other-
wise reimbursed under Medicare skilled
home health care); consumable goods
(such as incontinence supplies); home
repairs and safety modifications to the
home.1 Clients and families, other than
Medicaid participants, paid a 20-percent
copayment for demonstration services.
Case management and caregiver sup-
port services were reimbursed separately
from the capped demonstration benefit.
These services included caregiver educa-
tion and training, caregiver support
groups, and caregiver transportation to
education and support groups.  The costs
for these services were included in the
administrative budgets of the demonstra-
tion programs.
Eight sites, four in each model, partici-
pated in the demonstration.2 The sites
became operational in December  1989 and
served clients and their families until
November 30, 1994.  Eligibility for the
demonstration required a physician-certi-
fied diagnosis of an irreversible dementia
(e.g., Alzheimer’s disease or vascular
dementia), client enrollment in (or eligibil-
ity for) both Parts A and B of the Medicare
program, and residence in a community
setting in the demonstration site’s catch-
ment area.  Nursing home residents at the
time of enrollment were ineligible.
Although no restrictions were placed on a
participant’s ability to use community ser-
vices, persons receiving Medicaid case
management services at the time of appli-
cation (for example, through Medicaid
home and community-based care pro-
grams) were generally not accepted into
the demonstration. These individuals were
excluded because their case management
and benefits were equal to or greater than
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1 Additional, but seldom used, services included skilled nursing
and rehabiitation nursing therapies (i.e., speech, occupational,
physical; home health aide) home health aide, and home-deliv-
ered meals.
2 Model A (lower reimbursement-higher caseload) sites were
located in Champaign/Urbana, IL; Memphis, TN; Portland, OR;
and Rochester, NY.  Model B (higher reimbursement-lower
caseload) sites were located in Cincinnati, OH; Miami, FL;
Minneapolis, MN; and Parkersburg, WV.
that available through the demonstration.
This left the demonstration little opportu-
nity to affect client outcomes.  All exclu-
sions occurred prior to randomization.
Treatment or control group members
becoming eligible for such programs after
enrollment remained in the demonstration.
Enrollment into the demonstration was
voluntary.  Recruitment included informa-
tion about the program being a demonstra-
tion and the fact that some applicants
would be assigned to a control group.  The
demonstration was designed to maximize
the project’s ability to test the effectiveness
of the intervention, not specifically to test
its generalizability to the full eligible popu-
lation.  How the requirements of a demon-
stration may have influenced the decision
of the dementia population and their care-
givers about whether to apply for the pro-
gram is unknown.  Records were not main-
tained on individuals who contacted the
program, unless they submitted a complet-
ed application.  Randomized assignment of
cases was used to minimize any influence
of choice among such applicants.  This
design precluded testing what the treat-
ment effect would have been in a probabil-
ity sample of the eligible dementia popula-
tion.
Study subjects were recruited using
both physician referral and self-referral.
Data on applicants obtained from a screen-
ing questionnaire and physician referral
form were the basis for establishing eligi-
bility for the program.  Those found to be
eligible were then randomly assigned by
the evaluators to either the treatment
group (where they were eligible for case
management and service coverage), or
into a control group (where they continued
to receive their usual care).  Once enrolled
in the demonstration (either as treatment
or control), participants were given a semi-
annual reassessment throughout their par-
ticipation (i.e., to death, to 12 months fol-
lowing a permanent nursing home place-
ment, or to the end of study at 36 months).
Clients lost their eligibility for community
demonstration services and case manage-
ment once they had been permanently
placed into a nursing home.  The intake
assessments were conducted via in-person
interviews and the reassessments were
conducted predominantly via telephone.
Medicare claims data for each study sub-
ject also were obtained for the period start-
ing 12 months prior to enrollment, through
the 36 months of participation, death, or
health maintenance organization (HMO)
enrollment  A total of 4,151 participants
enrolled into the treatment group and
3,944 into the control group.3
Hypotheses
The intervention of case management
and community service reimbursement
had a strong, consistent, and positive
impact on the likelihood of using such
community-based, long-term care services
as homemaker/chore, personal care, com-
panion services, and adult day care.4
Treatment group clients were at least twice
as likely as control group members to use
one or more of these four services
(Newcomer et al., 1999b).  These out-
comes are consistent with the primary
objectives of the demonstration.
The analyses reported in the current arti-
cle examine whether increased access to
community care and case manager over-
sight had a secondary consequence related
to health care use and expenditures.  While
the demonstration was not explicitly direct-
ed to affecting health care use, reductions
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3 Applicants during the first 24 months of operation constituted a
closed panel of cases for the evaluation.  The programs contin-
ued to enroll members for 2 years after that so they could main-
tain a steady-state client-to-case-manager ratio.  Evaluation data
were not collected on these later enrollee cohorts.
4 Together these services accounted for more than 80 percent of
the services used by demonstration participants (consumable
supplies being the other most commonly used benefit).
in use are necessary for the program to
approach budget neutrality for Medicare.
Several hypotheses are tested related to
total Medicare health care expenditures for
participants, all of whom were in the
Medicare fee-for-service (FFS) system:
• Medicare Part A (largely hospital and
skilled nursing home inpatient care)
expenditures will be lower in the treat-
ment group compared with controls.
• Medicare Part B expenditures (inclusive
of physician and outpatient care, some
home health, and DME) will be higher 
in the treatment group compared with  
controls.
• Total expenditures combining Part A
and Part B will be lower in the treatment
group compared with controls.
• The treatment effect on Medicare Part A
and Parts A and B expenditures will be
greater in Model B than in Model A. 
• Medicare Part A and Parts A and B
expenditures will be lower in the site that
used  predominantly nurse case man-
agers than in sites with social worker
case managers.
Treatment effects were hypothesized to
occur, in part, because of home care work-
er contacts with the client with dementia
and their caregivers and regular contacts
between case managers and caregivers.
Such contacts potentially gave case man-
agers ongoing information about: (a) the
ability of the informal caregiver to provide
care and the adequacy of the care they pro-
vided; and (b) changes in the health and
functional status of the client.  Such infor-
mation, shared with the client’s health care
providers, may have had a preventive effect
in that it could facilitate interventions that
reduced avoidable physical deterioration,
hospitalization, and emergency room use.
Case manager involvement also had an
assumed potential (given requests by the
family or health care providers) to be
responsive to the care and support needs of
clients and caregivers after critical events
such as hospital stays, possibly reducing
home health costs and nursing home stays.
The case manager’s oversight and
patient advocacy are hypothesized to
decrease use of hospital-related (mostly
Part A) services, and increase use of ambu-
latory care (mostly Part B) services.
Combining Part A and Part B expenditures
permits evaluation of whether increased
ambulatory care expenditures associated
with greater medical management were
offset by decreased acute care expendi-
tures for hospital and nursing home care.
Demonstration treatment group partici-
pants in the Model B (i.e., higher
resource) program sites are hypothesized
to have lower health care expenditures
than were treatment group participants in
Model A (i.e., lower resource) sites due to
the greater availability of care manager
resources.  The Illinois program, which
featured only nurse care managers (and
not social workers), is hypothesized to
show lower total health care costs than the
other sites, due to the greater involvement
of demonstration nurses in clinical care.
Other sites generally used social workers
as case managers, although they had
access to nurse consultants.  (Refer to
Newcomer, Arnsberger, and Zhang, 1997
for a discussion of operational differences
in case management among demonstration
sites as measured by client chart reviews.)
These hypotheses were tested under
varying period and geographic aggrega-
tions.  Models were estimated for the
entire period that participants resided in
the community (the “entire exposure peri-
od,” and for each of up to 3 separate years
(year 1, year 2, and year 3) that they
resided in the community.  These period
analyses were conducted combining sub-
jects in all study sites.  Only the entire
exposure period was used in analyses for
each of the eight demonstration sites (com-
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munities).  The focus on study subjects
only during their residence in the commu-
nity (i.e., not in a nursing home) recognizes
that being in the community was a demon-
stration criterion for receiving case man-
agement and home care services.
Determining the effect on total expendi-
tures regardless of location (i.e., communi-
ty versus nursing home) would be con-
founded by the fact that a case would not be
affected by the demonstration’s resources
after entering a nursing home.  Site-specific
replications of the analysis recognize that
demonstration effects may vary among
communities due to several factors, includ-
ing the two different program models, with-
in-model operational differences, and/or
practice variations among the communities.
Methodology
The analyses were conducted using data
from caregiver assessment interviews
linked to Medicare claims records.  Claims
records were available only for beneficia-
ries who received their health care
through Medicare FFS  reimbursement
(n= 5,649), as service encounters within
managed care systems (e.g., HMOs) are
paid on a capitation basis and HCFA does
not receive service claims records for
those encounters.  
The study sample entered the demon-
stration from December 1989 through
November 1991.  Assessment data were
collected at baseline and semi-annually on
each case that continued to reside in the
community.5 The baseline instrument was
used for year 1 analyses.  The 12- or 24-
month assessments (if the instruments
were available or the immediately prior
one otherwise) were used for year 2 and 3
analyses, respectively.  Analyses based on
aggregations of cost over more than 1 year
used baseline instruments for client and
caregiver covariates.
Randomization produced highly compa-
rable groups of treatments and controls at
baseline, but covariates were used in the
analysis to increase the precision of the esti-
mates of the effect of the demonstration on
Medicare expenditures (by reducing unex-
plained variance in the outcome variable).
There were no differences in nursing home
placement or sample attrition (due to death
or other reasons) between treatment and
control groups (Miller et al., 1999).
The assessment instruments include
data on: client and caregiver functional sta-
tus, as measured by a version of the Katz
activities of daily living (ADL) scale (Katz
et al., 1963) and Lawton and Brody’s instru-
mental activities of daily living (IADL)
scale (Lawton and Brody, 1969); client cog-
nitive status, as measured by the mini-men-
tal status examination (Folstein, Folstein,
and McHugh, 1975); client behavioral
problems, as measured by an adaptation of
the index developed by Zarit, Todd, and
Zarit (1986); caregiver burden, as mea-
sured by a revised version of Zarit’s care-
giver burden scale (Zarit, Reever, and
Bach-Peterson, 1980); caregiver depres-
sion, as measured by the brief version of
the Geriatric Depression Scale (Yesavage
et al., 1983); and service utilization.  The
scale ranges are shown in Table 1.
Additional client and caregiver data
included: age; insurance; educational level;
living arrangement; ethnicity; marital sta-
tus; sex; relationship between client and
caregiver; and income.
The client measures generally follow the
Anderson framework of predisposing,
enabling, and need characteristics of
clients (Anderson and Newman, 1973).
Client measures were expanded to include
cognitive impairment (Bass, Looman, and
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5 Patients enrolling between May and November 1991 constitut-
ed a supplemental sample (n=2,310 cases, selected to assure the
evaluation of an adequate sample size for the full 36 months of
exposure in the demonstration.  Assessment data were collected
at baseline, 24 and 36 months for this group.
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Table 1 
Characteristics of the Analysis Sample
Treatment Group Control Group
Characteristic Count Percent Count Percent
Client Age 
20-64 Years 45 1.6 48 1.7
65-69 Years 280 9.7 253 9.1
70-79 Years 1,219 42.4 1,160 41.8
80-84 Years 693 24.1 700 25.2
85-90 Years 452 15.7 451 16.3
90 Years or Over 186 6.5 163 5.9
Client Sex (Female) 1,770 61.6 1,650 59.5
Client Race
White 2,471 85.9 2,379 85.7
Black 297 10.3 288 10.4
Hispanic 92 3.2 95 3.4
Other 15 0.5 13 0.5
Client Lives with Relatives 1,024 35.6 1,007 36.3
Client Lives in Own Home 1,851 64.4 1,768 63.7
Client Income
Less than  $5,000 242 8.4 212 7.6
$5,000 - $9,999 743 25.8 780 28.1
$10,000-$19,999 973 33.8 949 34.2
$20,000-$30,000 425 14.8 379 13.7
$30,000 or More 354 12.3 328 11.8
Unknown 138 4.8 127 4.6
Medicaid Recipient in Any Period 216 7.5 213 7.7
Medicare Supplemental Insurance 1,333 46.4 1,250 45.0
Entered Health Maintenance Organization (After Baseline) 65 2.3 64 2.3
Client Activities of Daily Living Limitations1
0-1 543 18.9 554 20.0
1.5-2 459 16.0 450 16.2
2.5-3 390 13.6 362 13.0
3.5-5 647 22.5 595 21.4
5.5-8 486 16.9 476 17.2
8.5-10 350 12.2 337 12.1
Client Instrumental Activities of Daily Living Limitations2
0-3 171 5.9 177 6.4
3.5-5.5 515 17.9 534 19.2
6-6.5 456 15.9 412 14.8
7-7.5 787 27.4 766 27.6
8 946 32.9 885 31.9
Client Mini-Mental Status Examination Score3
0 306 10.6 278 10.0
1-5 244 8.5 226 8.1
6-10 292 10.2 292 10.5
11-15 448 15.6 469 16.9
16-20 617 21.5 573 20.6
21-25 543 18.9 500 18.0
25-30 256 8.9 261 9.4
Missing 169 5.9 176 6.3
Client Behavior Problems4
0-4 439 15.3 385 13.9
5-7 625 21.7 577 20.8
8-10 717 24.9 723 26.1
11-13 649 22.6 609 21.9
14-19 430 15.0 471 17.0
Missing 15 0.5 10 0.4
See footnotes at end of table.
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Table 1—Continued
Characteristics of the Analysis Sample
Treatment Group Control Group
Characteristic Count Percent Count Percent
Caregiver Relationship to Client and Sex
Husband 465 16.2 410 14.8
Wife 839 29.2 827 29.8
Daughter 855 29.7 787 28.4
Son 237 8.2 242 8.7
Daughter-in-Law 105 3.7 119 4.3
Female Relative 179 6.2 198 7.1
Other 185 6.4 168 6.1
Missing 10 0.3 24 0.9
Caregiver Age
Under 70 Years 1,707 59.4 1,673 60.3
70-74 Years 350 12.2 335 12.1
75-79 Years 336 11.7 329 11.9
80-84 Years 236 8.2 223 8.0
85 Years or Over 111 3.9 103 3.7
Missing 135 4.7 112 4.0
Caregiver Income
Less than $10,000 228 7.9 250 9.0
$10,000- $40,000 721 25.1 667 24.0
$40,000 or More 407 14.2 412 14.8
Income Joint with that of Client 1,304 45.4 1.237 44.6
Missing 215 7.4 209 7.6
Caregiver Educational Attainment
Less than High School 603 21.0 572 20.6
High School Graduate 844 29.4 820 29.5
Some College 659 22.9 669 24.1
College Graduate 681 23.7 648 23.4
Missing 88 3.1 66 2.4
Caregiver Health Status (Fair/Poor) 660 23.0 641 23.1
Caregiver Activities of Daily Living Limitations1
0 2,376 82.6 2,288 82.5
1 or More 413 14.4 422 15.2
Missing 86 3.0 65 2.3
Caregiver Instrumental Activities of Daily Living Limitations2
0 1,932 67.2 1,898 68.4
1 269 9.4 246 8.9
1 586 20.4 562 20.3
Missing 88 3.1 69 2.5
Caregiver Stress and Burden Scale5
0-6 559 19.4 589 21.2
7-10 544 18.9 487 17.5
11-14 602 20.9 603 21.7
15-18 558 19.4 524 18.9
19-28 529 18.4 506 18.2
Missing 83 2.9 66 2.4
Caregiver Depression Scale6
0 228 7.9 238 8.6
1-2 766 26.6 747 26.9
3-4 648 22.5 632 22.8
5-6 456 15.9 448 16.1
7-8 302 10.5 305 11.0
9-15 383 13.3 329 11.9
Missing 92 3.2 76 2.7
1 ADL score is based on needing none, some or maximum assistance.  Scores range from 0 (low) to 10 (high) impairment. 
2 IADL score is based on needing none, some or maximum assistance.  Scores range from 0 (low) to 16 (high) impairment.
3 Mini-mental status examination values can range from 1 to 30.  Lower scores are indicative of greater impairment.
4 The behavioral problems index ranges from 0 to 19.  The higher the score, the greater the number of behavior problems.
5 Scores range from 0-36.  Lower scores equal lower stress and burden
6 Scores range from 0-15.  Lower scores reflect a greater likelihood of depression.
NOTES:  Chi-square analyses were used to test significant differences between groups.  No such differences were found.
SOURCE: Unpublished data from the Medicare Alzheimer's Disease Demonstration and Evaluation, 1989-1994.
Ehrlich, 1992), behavior problems, and
type of housing.  Caregiver attributes were
added to the model and grouped into par-
allel predisposing, enabling, and need
dimensions.  Caregiver attributes were
selected from those found in other studies
to influence the likelihood of service use.
Medical diagnoses and Medicare expen-
ditures were obtained from Medicare
claims history files.6 A subset of 16 major
diagnostic groups were selected from the
4,000 plus International Classification of
Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) codes used on Medicare
claims.  These aggregations are shown in
Table 2 and follow grouping procedures
developed by the Center for Health
Economics Research (Pope et al., 1996).
Cases were classified as having the listed
chronic condition if there was a qualifying
diagnosis on any available record.
A number of analyses were conducted
testing sensitivity of the prevalence counts
to the claim source (i.e., Part A versus Part
B, versus Parts A and B), and the number
of months used in classifying a case as hav-
ing the condition.  These analyses, for the
study’s chronic conditions, show that preva-
lence rates increased by a multiple of 2 or
even 3, comparing all period counts relative
to single 6-month or 12-month periods.
Similarly, prevalence counts generally dou-
bled when Parts A and B counts were com-
pared with Part A only reported diagnoses.
An abridged version of this analysis was
published (Newcomer et al., 1999b).
The period used to identify these diag-
noses was inclusive of the 12 months prior
to the client’s enrollment into the demon-
stration through their completion of the
study or earlier exit due to HMO enroll-
ment (n=129) or death (n=1998).  A small
group of clients (n=2) also had reduced
exposure months because they went into
HMOs and subsequently went back to reg-
ular Medicare FFS prior to or during their
demonstration enrollment.
The operating assumption when using
this extended exposure period for diagnos-
tic classification was that any mention of a
chronic condition implied that the existence
of the condition preceded demonstration
enrollment.  Acute conditions (such as
injuries, fractures, or nutritional problems)
were not used as control variables as these
are associated with incidents or care out-
comes.  Prevalence rates of chronic condi-
tions treated as risk factors are shown in
Table 3.  These data affirm the effectiveness
of the randomization in achieving compara-
ble groups, and they provide descriptive
information about the differences in preva-
lence among the various conditions.
In analyses with all sites combined, a set
of dummy variables representing the
demonstration sites was included, omitting
a reference site whose expenditures were
closest to the median expenditures among
all sites.  This facilitates comparison of any
one site to the median performance of all
sites in the demonstration.  Table 4 shows
the sample size by site.
Medicare expenditures, the dependent
variable in the analysis, were based on the
allowed amounts indicated on each claim
record.  For most claim files this included
the amount paid by Medicare, plus
deductibles and coinsurance, and any addi-
tional amount paid by the recipient.  For
each subject the exposure within a given
period was limited by their eligibility for
Medicare, the date of permanent nursing
home placement, mortality, and loss to fol-
lowup.  Claims spanning periods were pro-
rated.  All claims were summed within
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6 For Part A, these included hospital inpatient, nursing facility
inpatient, hospital outpatient, home health, and hospice claims
files.  For Part B, there were physician and home health, and a
DME file.
each period and an annualized total was
calculated by summing expenditures in the
period of interest (i.e., year 1, year 2, year
3, or the entire exposure period from their
date of randomization up to 3 years) divid-
ing the result by the number of exposure
days in the period to get a daily rate, and
then multiplying by 365 to create an annu-
al rate.  In statistical calculations (including
group means and regression analyses),
exposure days was included as a covariate
to ensure that cases with few days and
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Table 2
Chronic Conditions and Their Defining Diagnostic Codes
Cancer (Except Minor Skin Cancer)
Any Diagnosis: 14, 15, 16, 170-1729, 174-179, 18, 1800, 1801, 1808, 1809, 181, 1820, 1821-1849, 185, 19, 190, 
1940-1991, 2, 20, 23, 230, 239, 7950, 7951
Cerebrovascular Aneurysm
Any Diagnosis: 436, 4373
Cerebrovascular Disease Events, Other 
Any Diagnosis: 438, 439 
Congestive Heart Failure
Any Diagnosis: 39891, 40403, 40411, 40491, 40493, 428, 4280, 4281, 4289
Coronary Artery Disease
Any Diagnosis: 4110, 4111, 4118, 41181, 41189, 412, 4130, 4131, 4139, 4140, 41400, 41401, 4148, 4149, 4297
Diabetes (with and Without Complications)
Any Diagnosis: 25, 250, 25000, 25001-3, 25010-13, 25020-2323, 25030-33, 25040-43, 25050-53, 25060-63, 25070-73,
25080-83, 25090-93, 2510-13, 3620, 36641, 7902, 7915, 7916
Liver/Gall Bladder/Pancreas Disease
Any Diagnosis: 070, 1514, 251, 2518, 570, 571, 5710-19, 572, 5720-28, 573, 5730, 5734, 5738, 5739, 574, 57400, 57401,
57410, 57411, 57420, 57421, 57430, 57431, 57440, 57441, 57450, 57451, 575, 5750, 5751-59, 576, 5760-
69, 577, 7824, 7891, 7895, 7904, 7905, 7933, 7948
Acute Myocardial Infarction
Any Diagnosis: 41, 410, 4100, 41000, 41001-2, 4101, 41010-12, 4102, 41020-22, 4103, 41030-32 ,4104, 41040-42, 4105,
41050-52, 4106, 41060-62, 4107, 41070-72, 4108, 41080-82, 4109, 41090-92, 412
Nerve Problems, Paralysis (Excludes Coma or Injuries)
Any Diagnosis: 342, 3430-34, 3438, 3439, 344, 3440, 3441, 3443, 3444, 3446, 34460, 3448, 3449, 7814
Nerve Problems, Peripheral  (Excludes Paralysis)
Any Diagnosis: 350-7, 7307, 9529, 953-56
Nerve Problems, Other Degenerative Nervous System Conditions
Any Diagnosis: 013, 014, 015, 332, 3320, 335, 336, 337, 340, 341, 342, 343, 344
Other Arthropathies Including Rheumatoid Arthritis
Any Diagnosis: 7110-16, 7193-99, 720-21
Pulmonary Disease, Chronic Obstructive Pulmonary Disease/Asthma/Emphysema
Any Diagnosis: 01140, 1370, 491, 4910-12, 49120, 49121, 4918, 4919, 492, 4920, 4928, 493, 49300, 49301, 49310,
49311, 49320, 49321, 49390, 49391, 494, 496, 5081, 5100, 5109, 515, 5183
Renal Disease
Any Diagnosis: 0160, 27410, 27411, 403, 404, 58, 590, 591, 592, 593, 7880, 7885, 7944, 866
Substance Abuse/Alcoholism
Any Diagnosis: 291, 292, 303-5, 3050, 3052-59, 4255, 571, 5710, 5711-13, 5715, 5353, 7903
Vascular Disease, Peripheral
Any Diagnosis: 440, 4400, 4401, 4402, 44020, 44021, 44022, 44023, 44029, 4408, 4409, 443, 4430, 4431, 44381, 44389,
4439, 4460-62, 44620-21, 44629, 4463, 4464-67, 4470-81, 4489, 5570, 5571, 5579, 7854
SOURCE: Unpublished data from the Medicare Alzheimer's Disease Demonstration and Evaluation, 1989-1994.
large expenditures did not disproportion-
ately influence results by inflating the
mean daily expenditure rate.  
Table 5 shows the annualized means and
standard deviations for each year and
entire exposure period in the analysis for
Part A, Part B, and the combined Parts A
and B expenditures. Annualized expendi-
tures for yearly periods and the entire
exposure period were used in the analysis
to assess the sensitivity of the findings to
different time intervals.  Expenditures dur-
ing the entire exposure period in the
demonstration were specifically used for
two reasons: (1) whereas single year peri-
od expenditures are commonly used as
dependent variables in risk adjustment
methodologies, the resulting estimates
generally have wider variance than those
for multiple year period expenditures; and
(2) in a cohort study (such as this one),
there are increasingly fewer cases avail-
able in each period after baseline.  The
combination of more variance and fewer
cases results in analyses with lower statis-
tical power than analyses that use data for
the full exposure period
The observed effect sizes (i.e., the dif-
ference between treatment and control
group means divided by the pooled stan-
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Table 3
Prevalence of Selected Chronic Health Conditions Found on Any Medicare Claims Record
Treatment Group Control Group
Conditions N with Condition Percent N with Condition Percent
Cancer (Except Minor Skin Cancer) 546 19.0 542 19.5
Diabetes (with and without Complications) 614 21.4 621 22.4
Eyes/Ears
Blindness or Substantial Vision Defect 52 1.8 44 1.6
Hearing Loss 132 4.6 122 4.4
Vertigo/Dizziness 263 9.1 282 10.2
Heart and Vascular Systems
Aneurysms (Other than CVA) 45 1.6 45 1.6
Cerebrovascular Aneurysm 693 24.1 647 23.3
Cerebrovascular (Other) Disease Events 1,159 40.3 1,096 39.5
Congestive Heart Failure 811 28.2 760 27.4
Coronary Artery Disease 923 32.1 919 33.1
Hypertension (Any) 1,335 46.4 1,211 *43.6
Myocardial Infarction 257 8.9 272 9.8
Peripheral Vascular Disease 745 25.9 708 25.5
Liver/Gall Bladder/Pancreas Diseases 256 8.9 261 9.4
Musculo-Skeletal System
Intervertebral Disorders 282 9.8 259 9.3
Osteoarthritis Related Disorders 700 24.3 735 26.5
Other Arthropathies 889 30.9 908 32.7
Other Connective Tissue Disorders 85 3.0 89 3.2
Nervous System
Degenerative Nervous System Conditions 484 16.8 464 16.7
Paralysis (No Coma or Head Injuries) 208 7.2 221 8.0
Peripheral Nerve Problems 135 4.7 146 5.3
Pulmonary System
COPD/Asthma/Emphysema 769 26.7 726 26.2
Tuberculosis (Pulmonary Only) 57 2.0 51 1.8
Renal System Diseases 439 15.3 409 14.7
*p <0.05 using Fisher’s statistical test, 2-tailed.
NOTES: COPD is chronic obstructive pulmonary disease.  CVA is cerebrovascular aneurysm.  The diagnostic categories included in each of the 
listed conditions are shown in Table 2.
SOURCE: Unpublished data from the Medicare Alzheimer's Disease Demonstration and Evaluation, 1989-1994.
dard deviation of the two groups) are .06,
.03, and .06 respectively comparing Part A,
Part B, and Parts A and B treatment and
control case expenditures in year 1 for all
cases combined; and 0.08, 0.05, and 0.08
respectively comparing Part A, Part B, and
Parts A and B treatment and control case
expenditures over all periods.  An effect
size of 0.06, assuming a standard deviation
of $11,800 translates into a difference of
$709; 0.06 of a standard deviation of
$14,500 equals $870.  Approximately 5,300
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Table 4
Number in Analysis Sample, by Site and Available Claims Data
Total Part A Parts A and B
Sites Enrolled1 Enrolled2 Enrolled
Model A Total 3,965 2,995 2,883
Treatment 2,029 1,520 1,467
Control 1,936 1,475 1,416
Illinois 999 920 881
Treatment 515 475 454
Control 484 445 427
New York 1,048 761 732
Treatment 530 383 374
Control 518 378 358
Portland 932 430 414
Treatment 485 212 207
Control 447 218 207
Tennessee 986 884 856
Treatment 499 450 432
Control 487 434 424
Model B Total 4,130 2,655 2,518
Treatment 2,122 1,355 1,288
Control 2,008 1,300 1,230
Florida 1,157 726 675
Treatment 593 371 346
Control 564 355 329
Minnesota 1,417 604 585
Treatment 738 314 305
Control 679 290 280
Ohio 927 825 779
Treatment 481 423 401
Control 446 402 378
West Virginia 629 500 479
Treatment 310 247 236
Control 319 253 243
Total All Sites 8,095 5,650 5,401
Treatment 4,151 2,875 2,755
Control 3,944 2,775 2,646
1 The total sample excludes persons enrolled into the demonstration who died or entered a nursing home within the first 30 days after enrollment,
and persons who were living in nursing homes at the time of enrollment and who failed to return to the community.  It includes persons who were
enrolled in an HMO.  
2 The difference in cases between the total sample and those eligible for Part A reflects the number of enrollees who were members of an HMO at
baseline.  The difference between the Part A sample size and the Parts A and B sample size occurs because Part B claims were unavailable until
January 1, 1991.  Any demonstration plan member dying or joining an HMO prior to that date did not have Part B claims records available, consequently
Parts A and  B expenditures could not be calculated prior to that date.
NOTE: HMO is health maintenance organization.
SOURCE: Unpublished data from the Medicare Alzheimer's Disease Demonstration and Evaluation, 1989-1994.
cases are needed to have a statistical power
of 0.75 (assuming an alpha of 0.05 and a
one-tailed test) to observe a difference of
this magnitude given the variance.
Model development consisted of several
steps.  The initial step used the client and
caregiver attribute interview items shown
in Table 1.  Using total Medicare expendi-
tures as the dependent variable these were
reduced to a set of 15 covariates using
backward stepwise regression analysis.
Interaction effects between treatment and
these covariates were tested with none
found to be consistently significant.  The
second step added the 26 chronic condi-
tion variables shown in Table 3 and used a
backward stepwise methodology to adjust
for collinearity among chronic conditions
that were added at this step.  The statisti-
cally significant covariates from step 1 and
treatment group were forced into this
analysis.  Both untransformed and log-
transformed dependent variables were ana-
lyzed, and both were found to yield residu-
als which did not fit a normal distribution.
To respond to the non-normality issue, a
two-stage analysis was conducted.  It con-
sisted of a multivariate logistic regression, a
bootstrap regression, and further methods
to combine the results of the two-stage
model.  The dependent variable for the
logistic model was a binary indicator vari-
able that was 1 when there was any Part A
expense during the period, and zero if there
was no expense.  (A variation on this thresh-
old was tested: expenses of less than $500.
It produced similar results.)  The dependent
variable in the bootstrap regression was the
log of the positive expenses, and was per-
formed only on the subjects who had an
expense.  The independent variables in both
models were the same, except that certain
low-incidence dummy variables were elimi-
nated from the logistic models because
small cell size (fewer than five subjects)
caused convergence problems.  Each model
also included a dummy variable for those
cases having fewer than 20 percent expo-
sure days in the period, relative to the max-
imum possible days.  This controlled for the
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Table 5
Annualized Mean Medicare Expenditures, by Period
Part A Part B Parts A and B
Period Total Treatment Control Total Treatment Control Total Treatment Control
Year 1
Total Cases 5,648 2,874 2,774 5,151 2,641 2,510 5,151 2,641 2,510
Mean Expenditures 5,284 4,983 5,596 1,791 1,759 1,825 7,526 7,169 7,898
Standard Deviation 9,695 9,626 9,760 2,484 2,572 2,387 11,544 11,751 11,316
Year 2
Total Cases 3,665 1,870 1,795 3,665 1,870 1,795 3,665 1,870 1,795
Mean Expenditures 6,023 5,743 6,317 1,673 1,634 1,714 7,697 7,378 8,032
Standard Deviation 10,497 9,948 11,036 2,687 2,638 2,739 12,463 11,812 13,105
Year 3
Total Cases 2,255 1,184 1,071 2,255 1,184 1,071 2,255 1,184 1,071
Mean Expenditures 7,067 6,791 7,367 1,833 1,736 1,939 8,901 8,526 9,305
Standard Deviation 12,364 12,218 12,524 3,006 2,931 3,084 14,458 14,127 14,813
All Periods
Total Cases 5,649 2,875 2,774 5,170 2,652 2,518 5,170 2,652 2,518
Mean Expenditures 5,862 5,578 6,161 1,758 1,709 1,810 7,898 7,555 8,260
Standard Deviation 6,922 6,822 7,020 1,911 1,930 1,890 8,533 8,486 8,576
NOTES: Means are based on an annualization of expenditures for each case alive and living in the community at the start of the period shown.
Counts differ in year 1 between Part A and Part B due to unavailable physician payment records prior to 1991.  Partial use in a period was annual-
ized by dividing total expenditures in the period by the number of exposure days and multiplying by 365.  Statistical calculations further weighted
each case by the proportion of days in the exposure period.
SOURCE: Unpublished data from the Medicare Alzheimer's Disease Demonstration and Evaluation, 1989-1994.
fact that fewer exposure days would cause
less likelihood of any expense, but given
that there was an expense, would cause
greater average expenses.
From the regression results, the esti-
mated expense for each subject was calcu-
lated as the estimated probability of an
expense (from the logistic model), times
the anti-log of the estimated log expense
(from the bootstrap regression), times a
“smear factor.”  The smear factor is the
mean anti-log of the residuals from the
regression (Duan, 1983).  Following a sug-
gestion from Manning (1998), smearing
factors were calculated for the treatment
and control groups separately. These pro-
duced results similar to the smearing fac-
tor with all cases combined.  The reported
results reflect the combined factor.
The estimated treatment effect was cal-
culated for each subject based on the dif-
ference between their estimated expense
assuming they had been in the treatment
group, minus their estimated expense
assuming they had been in the control
group.  In this way, the simultaneous
effects of the covariates could be applied to
both the logistic and regular regression
models (Haber, 1996).  The weighted mean
of the individual treatment effects was used
to estimate the overall treatment effect.
A series of 200 bootstrap replications were
performed to obtain a simulated distribution
of each point estimate of the overall treat-
ment effect described previously.  Each
replication consisted of a sample of cases
taken with replacement from the original
sample.  A 95-percent confidence interval
was calculated consisting of the 5th and
196th order statistic for the distribution
obtained from the resampling.  A non-para-
metric p-value testing the null hypothesis
that the treatment effect was zero was then
calculated.
Because of the presence of statistically
significant interaction terms for treatment
and site, and regional differences in pre-
vailing service unit prices, separate analy-
ses were also conducted for each site.  This
afforded the opportunity to more clearly
assess the performance of each program at
the level of each community, where ran-
domization produced equivalence between
those in treatment and control groups.
Findings
Table 6 compares the logistical regres-
sion results using two alternative thresh-
old values for the dependent variable.
Separate models were estimated for each
row in the table.  All models used the
covariates shown in Tables 1 and 3.  Table
6 shows the percent of the sample having
Part A expenditures of the qualifying level.
The immediately following column shows
the odds ratio or likelihood that those in
the treatment group had this level of
expenditures in the period.  These analy-
ses might be seen as a non-conservative
test of the treatment effect because they
require that there be only a reduced likeli-
hood of expenditures. The preponderance
of period and site models show a pattern of
a lower likelihood for Medicare Part A
expenditures among those in the treat-
ment group, but only one of these odds
ratios is statistically significant.  
Table 7 summarizes the results of the
bootstrap regressions, comparing the
demonstration’s estimated treatment effect
on annualized expenditures.  Several meth-
ods of aggregating the dependent variable
data are used.  Table 7 shows estimated
treatment effect results from the regres-
sion models in which all sites are included
together.  Annualized mean expenditures
are shown by year and for the entire expo-
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sure period.  Also shown here are the treat-
ment effect results based on similar boot-
strap regression models estimated for each
demonstration site (community) consid-
ered separately.  The site level regression
models report annualized expenditures for
the entire exposure period.  Three sets of
columns are used to show the estimated
treatment effect on various groups of
Medicare annualized expenditures.
Separate regression models were estimat-
ed for each cell in this table, using the
client, caregiver, and health condition
covariates shown previously in Tables 1
and 3.  In the interest of presentation parsi-
mony, only parameter estimates for treat-
ment dummy variables are shown.  The
results shown use the likelihoods derived
from the (any expenditures) dummy vari-
able in the stage-one model (Table 6).
Similar analyses were conducted using the
less than $500 level.  These produced find-
ings comparable those in Table 7, and have
not been shown.
Several patterns emerge from these
results.  For all sites combined, there is a
tendency for a negative treatment effect on
Medicare Part A and Parts A and B expen-
ditures when expenditures are annualized
over all periods, but these results are not sta-
tistically significant.  For each year consid-
ered separately, there is a similar tendency
for a negative treatment effect (i.e., reduced
expenditures) on Medicare Part A and Parts
A and B expenditures, however, again these
results do not obtain statistically significance
at a 0.05 level.  These results do not support
the hypothesis that the demonstration inter-
vention would lower Medicare Parts A and A
and B expenditures.
Again, for all sites combined, the esti-
mates of the treatment effect on Part B
expenditures are also not statistically signif-
icant.  These findings do not support the
hypothesis that the demonstration would
lead to higher Part B expenditures for treat-
ments compared with controls, and suggest
that the demonstration program, on aver-
age, did not stimulate or facilitate more
access to ambulatory health care than was
obtained by those in the control group.
Five of the individual sites showed dif-
ferences in expenditures for treatments
and controls, relative to at least one type of
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Table 6
Comparing the Likelihood of Medicare Part A Expenditures Among Treatment and 
Control Groups
Expenses Less than $500 Any Expenses
Percent Odds Confidence Percent Odds Confidence
Period >0 Ratio Interval >0 Ratio Interval
All Sites
All Periods 69.3 0.99 0.87 to 1.13 86.9 0.96 0.87 to 1.13
Year 1 54.4 0.96 0.86 to 1.08 75 0.93 0.82 to 1.06
Year 2 53.6 0.96 0.82 to 1.12 72 0.9 0.77 to 1.06
Year 3 55.8 1.03 0.85 to 1.26 74.2 0.88 0.71 to 1.09
Model A Sites
Illinois, All Periods 69.7 0.84 0.60 to 1.17 86.3 0.96 0.62 to 1.50
New York, All Periods 60.6 0.94 0.66 to 1.34 88.8 1.22 0.70 to 2.17
Oregon, All Periods 62.3 1.01 0.61 to 1.66 85.3 0.91 0.45 to 1.84
Tennessee, All Periods 76.9 1.38 0.92 to 2.09 88.2 0.92 0.54 to 1.56
Model B Sites
Florida, All Periods 74.3 1.39 0.90 to 1.17 85.1 1.43 0.84 to 2.46
Minnesota, All Periods 59.3 0.89 0.59 to 1.34 81.3 0.91 0.54 to 1.51
Ohio, All Periods 70.2 0.84 0.58 to 1.21 86.9 0.59 0.36 to 0.95
West Virginia, All Periods 78.2 0.84 0.52 to 1.36 93.2 0.78 0.34 to 1.74
NOTE: Confidence interval is 95 percent likelihood that true odds ratio is within this range.
SOURCE: Unpublished data from the Medicare Alzheimer's Disease Demonstration and Evaluation, 1989-1994.
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Medicare coverage.  These results were
statistically significant in two sites.
Whether for Part A, Part A and B, or mere-
ly Part B expenditures in at least three the
sites showed increased cost (albeit statisti-
cally non-significant). Illinois (a Model A
site with nurses as care managers) did not
show the expected estimates of expendi-
tures that were significantly lower for the
treatment compared with the control
group.  Tennessee (also a Model A site)
and Florida (a Model B site) showed esti-
mates of Medicare Part A expenditures
that were significantly lower for treatments
compared with controls.  This relationship
also held for Part A and B expenditures,
although the coefficient was just over the
0.05 level in Tennessee (p >0.06).  West
Virginia (a rural Model B site) showed sta-
tistically significant higher Part B expendi-
tures for treatments compared with con-
trols.  These results, at the site level, offer
limited support for three of four study
hypotheses.
The study’s final hypothesis was that par-
ticipants in the higher resource demonstra-
tion programs (Model B) would have lower
Medicare expenditures than participants in
the lower resource programs (Model A).
This hypothesis was tested both using the
results of the individual site regression
models discussed previously and through a
t-test of the mean effects among the group
of sites in each model.  The t-test results
showed no difference between models, and
as seen from Tables 6 and 7, neither Model
produced a consistent pattern of lower
Medicare Part A and Medicare Parts A and
B expenditure estimates for treatments
compared with controls.
An alternative set of bootstrap regressions
was estimated using a continuous measure
of exposure days instead of the binary mea-
sure.  These models generally produced
point estimates of the treatment effect—
approaching those in Table 5, but with wider
confidence intervals than those shown in
Table 7.  The loss of precision dropped
Florida from having a statistically significant
difference in Part A expenditures and
Tennessee from the combined Parts A and
B expenditures.  The all period/all sites
model did become statistically significant.
The results reported in Table 7 have been
used because they have more precision.
CONCLUSIONS
The Medicare Alzheimer’s Disease
Demonstration and Evaluation randomly
assigned about one-half of a large group of
voluntary applicants into a treatment group
that had access to a limited Medicare com-
munity care service benefit and routine
monitoring and other assistance from a
case manager.  Those randomly assigned to
the control group continued to receive stan-
dard care.  The demonstration was not
expressly designed to affect medical care,
but the increased access to community care
obtained by those in the treatment group
suggested the possibility of a secondary
effect on health care.  Five hypotheses
were tested controlling for a variety of
attributes of persons with dementia, includ-
ing functional, cognitive, and physical
health conditions; and of caregivers, includ-
ing relationship to client, and physical and
mental health status.  These hypotheses
were tested for participants that obtained
services from the regular Medicare FFS
system, and thus, for whom there were
health care service claim records.
Overall, these findings provide only lim-
ited support for the hypothesis that the
demonstration (which did not expressly
coordinate with primary care physicians)
reduced hospital utilization and other Part
A expenditures among treatment group
members using Medicare FFS.  Five sites
showed reduced treatment group expendi-
tures for Part A, and/or the combination of
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Part A and B expenditures.  These differ-
ences reached or approached statistical
significance in two sites.  Treatment group
members, when considered as a single
group were not found to have lower
Medicare Part A expenditures than control
group members with comparable health
status.  This finding was consistent in mod-
els using annualized expenditures with all
sites combined for the clients’ full expo-
sure period of up to 36 months, and for
each year in the demonstration.
The third hypothesis, that the demon-
stration program would increase access
and use of Part B services, was not gener-
ally supported.  Only one site had treat-
ment group members with higher predict-
ed expenditures than those in the control
group.  A related hypothesis, that the one
site using only nurses as case managers
would have more effect on health care
expenditures than the sites using social
workers (usually with nurses available as
consultants),  also was not supported.
The hypothesis that Model B would
have a stronger treatment effect on
Medicare expenditures  relative to Model
A was not supported.  There was no
demonstrable advantage relative to lower-
ing Medicare expenditures for the high
resource program (Model B) compared
with the low resource program (Model A).
One of the Model B sites achieved
Medicare (Part A and Parts A and B)
expenditure savings for the treatment
group that were statistically different from
their respective control groups, and one
site even produced higher costs, although
this finding was non-significant.  On the
other hand, one Model A site also showed
treatment groups with lower expenditures
than their controls.  
All of this supports a conclusion that,
while site differences undoubtedly have
some importance in the relative success of
the intervention, there is no evidence that
the high resource program (at least within
the range of resources made available) pro-
duced more expenditure savings relative to
those in usual FFS Medicare within those
communities than did the lower resource
program.
Comparisons of model effects are com-
plicated by the fact that clients were ran-
domized within communities, not between
models.  Thus, the demonstration reflects
a four-site replication of each model.
Whatever practice pattern and other situa-
tional factors that operated locally to affect
Medicare use were not randomly distrib-
uted among the models.  A larger sample
of communities or another mix of commu-
nities within each model may produce a dif-
ferent finding.  Perhaps the more germane
conclusion to be drawn is that the demon-
stration program (ignoring model) did
achieve some savings in at least two com-
munities, and that there was a tendency
toward reduced expenditures in the major-
ity of the sites.  The failure of the treatment
program to achieve reduced Medicare
expenditures consistently among all sites
and for all periods suggests the conserva-
tive conclusion that the mere presence of a
case manager does not assure increased
access to health care or to the prevention
of conditions that may otherwise increase
Medicare expenditures.  
One reason for a possible absence of a
consistent effect is suggested by the wide
variation in expenditures (especially within
single years).  This raises the possibility
that case manager involvement may pro-
duce at least a short-term increase in
expenditures for some cases.  Further, esti-
mates of the demonstration program effec-
tiveness are most favorable when multi-
year expenses were averaged together.
This suggests that steady-state program
effects on Medicare expenditures may be
relatively long term and require a sus-
tained intervention.  A third qualification is
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that the program was targeted to caregiver
support and community service provision,
not to coordination with primary care
physicians or health care risk management
processes.  The tendency for some cost
reductions among the treatment group, in
spite of this, suggests the potential for fur-
ther cost reductions in situations where
more attention is directed to the health care
management of this population.  Of particu-
lar note in this regard, is the high propor-
tion of cases with one or more significant
chronic health condition.  For example, as
shown by Medicare claims records, more
than 20 percent had diabetes, more than 25
percent had congestive heart failure,
almost one-third had coronary artery dis-
ease, and more than 25 percent had some
form of pulmonary disease.
A more cautionary viewpoint arises from
the possibility that the demonstration may
have attracted a population with higher
than average cost among those with
dementia.  Among the factors possibly
influencing this were the availability of
care coordination and community services.
These could be expected to be more
sought after by those needing this type of
assistance.  Such selection or choice fac-
tors have been mitigated in the demonstra-
tion using randomization, but a fully opera-
tional program or a program more oriented
to the time of one’s initial dementia diag-
nosis could be expected to have a broader
cross section of enrollees.  Under such cir-
cumstances, Medicare savings relative to
program costs could be less than those
observed in the demonstration, unless
there is an effective targeting of care man-
ager resources and benefits.
Accepting the evidence (or potential) of
lower Medicare expenditures for treatment
cases relative to controls in some commu-
nities and circumstance, there is still the
issue of whether the case management and
community service intervention, as imple-
mented, was cost effective in lowering
those expenditures.  In other words, did
the cost of the intervention, even in the
most favorable sites, exceed the cost sav-
ings resulting from reductions in Medicare
expenditures?  The following illustrates the
demonstration performance that would be
needed to show cost effectiveness of the
demonstration in lowering Medicare
expenditures. 
A first assumption is that the treatment
effect parameter estimates shown in Table
7 are indicators of the true average treat-
ment effects among a cohort of clients over
time (ignoring whether or not the coeffi-
cients are statistically significant).  A sec-
ond assumption concerns the average cost
of the case management intervention itself.
For the sake of simplicity, the average
annual salary for a full time equivalent case
manager is set at $30,000 and the adminis-
trative overhead, home visit and other oper-
ating expenses are set equal to the annual
salary.  For a Model A site, with a ratio of 1
case manager per 100 clients, this produces
an annual cost per client of $600 or $50 per
month.  For the Model B sites with a 1:30
case manager to client ratio the annual cost
per client is $2,000 or $167 per month.
Based on these rates, two Model A sites
with a combination of lower staffing costs
and somewhat larger treatment effects
showed (or approached) a net savings rela-
tive to additional case-management costs
for Part A and Parts A and B expenditures.
One of the Model B sites reduced average
Medicare expenditures enough to offset
their estimated staff and operational costs.
This is true using both the actual treatment
parameter estimates for each site, and the
average treatment parameter estimates
among all Model B sites combined.  If the
Model B per client cost were set at the
Model A rate, two sites would show net
savings for Part A, and one for Part A and
B combined.
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The preceding comparisons do not
include the cost of the additional Medicare
benefits obtained by treatment group par-
ticipants under the demonstration waiver
for community care services.  These aver-
aged more than $200 a month in Model A
and $300 per month in Model B.  When an
average monthly benefit of $200 is added to
the $600 cost for the case manager and
other operational costs, one Model A and
one Model B site reached or approached
budget neutrality (defined by combining
Medicare Part A and B expenditures).
These calculations do not include or con-
sider any offsetting savings from nursing
home care, because analysis reported else-
where found no demonstration linked
reductions in nursing home care (Miller et
al., 1999).  However, it is possible that
reductions in hospitalization could also
reduce nursing home placements.
As with many other national demonstra-
tions, a number of questions are raised that
highlight either: (a) limitations of the design
of the particular project intervention; or (b)
methodological issues that might inform
further work in this area.  One limitation of
this study is that results pertain only to ben-
eficiaries who use the regular Medicare
FFS system.  In that system, it may be diffi-
cult or impossible to create appropriate
financial incentives to reduce overall costs,
unlike the Medicare HMO sector, where
there is an incentive to reduce costs.  
A second limitation is that the program
was not expressly designed for case man-
agers to work with health care providers in
the identification and management of high-
risk cases.  Although this occurred to vary-
ing degrees within each site, including in
response to the request of family members
and providers, it was not explicit or common
in any program.  Whether more attention to
this, especially among cases with complex
chronic conditions, would be effective has
not been fully tested in the demonstration
program design.  A further refinement in
case targeting may be an important contin-
uing step to reducing per client cost, and an
essential step in beginning to provide a cost
effective program.  Examining caregiver
attributes and their relationship to pre-
ventable health care episodes (such as
injuries, medication mismanagement, inad-
equate nutrition, or skin care), issues not
examined in these analyses, may also be a
productive area for further research into
case targeting risk factors.
Another needed refinement is in the clin-
ical efficacy of treatment for high-risk
cases, whether these result from chronic
conditions or other factors.  Finding a high-
risk case does not by itself assure that an
effective care plan can be designed or
implemented.  Exploration of possible
modes of communication and collaboration
between caregivers (whether family mem-
bers or paid providers) and care managers,
and between care managers and health
care providers was not a subject tested in
depth in the demonstration.  Further work
in this area may be productive.  Also impor-
tant is gaining a better understanding of
the health care use of those with dementia
and other chronic conditions.  What por-
tion of the expenses incurred by this popu-
lation are resultant from poorly managed
chronic conditions?  What practice inter-
ventions may be helpful in improving this
care?  Can coordination among community
and health care providers be achieved?
Are there any chronic conditions where
such coordination is particularly helpful?
Finally, relative to the question of quanti-
tative evaluation of the cost effectiveness of
programs such as this demonstration,
there is a need to be cognizant of the dif-
ferential findings that arise among individ-
ual sites, and over single versus multiple
years.  Sampling theory speaks to con-
cerns like homogeneity bias in cluster sam-
ples and the issue of within-group versus
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between-group variation.  Sites and time
periods are clusters, and expenditures by
an individual within the same period often
are not independent events and they may
be affected by community-specific practice
patterns.  While this demonstration had
sufficient power to detect an effect size of
0.15  in seven of the eight sites, the total
number of sites (four in each model) was
insufficient to address the within-and-
between group problem.  More fixable,
from a research cost standpoint, are the
time aggregations that are used.  The find-
ings from this article suggest that treat-
ment effects may be more discernible
when expenditures are averaged over mul-
tiple years rather than using only the events
of a single year.  Average expenditures over
time also are likely to be a better reflection
of the performance of a steady-state pro-
gram.  Such a finding may have implica-
tions for risk adjustment methods based on
a single year of expenditure data, as well as
for the future evaluation of interventions.
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